Methods of inhibiting Helicobacter pylori

Details Methods of inhibiting Helicobacter pylori Methods of inhibiting Helicobacter pylori

1998-06-30

2001-02-20

Housel, James C. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S195110, C435S032000

Reexamination Certificate

active

06190667

ABSTRACT:

This invention relates to methods of screening molecules capable of inhibiting the survival of Helicobacter, particularly
Helicobacter pylori,
in vivo by specifically inhibiting the activity of UreI, to the molecules identified by these methods, and to the use of these molecules to treat or prevent Helicobacter infection.
BACKGROUND OF INVENTION
Helicobacter pylori
is a microaerophilic Gram-negative bacterium, which colonizes the gastric mucosa of humans (10).
H. pylori
is associated with gastritis and peptic ulcer disease and has been shown to increase the risk of gastric cancers. Urease is a major virulence factor of
H. pylori.
It is involved in neutralizing the acidic microenvironment of the bacterium and also plays a role in
H. pylori
metabolism (11, 26).
The urease region of the
H. pylori
genome is composed of two gene clusters common to all strains (9 and FIG.
1
), one comprising the ureAB genes encoding the structural urease subunits and the other containing the ureEFGH genes encoding the accessory proteins required for nickel incorporation into the urease active site. The ureI gene lies immediately upstream from this latter gene cluster and is transcribed in the same direction (FIG.
1
). The ureA, ureB, ureE, ureF, ureG, ureH, and ureI genes and gene products have been described and claimed in U.S. Pat. No. 5,695,931 and allowed patent application Ser. No. 08/472,285, both of which are specifically incorporated herein by reference.
The distances separating ureI from ureE (one base pair, bp) and ureE from ureF (11 bp) suggest that ureI-ureE-ureF constitute an operon. Cotranscription of ureI and ureE has been demonstrated by northern blot analysis (1). An
H. pylori
N6 mutant with a ureI gene disrupted by a MiniTn3-Km transposon was previously described by Ferrero et al. (1994) (13). This strain (N6-ureI::TnKm-8) presented a urease negative phenotype, so it was concluded that ureI was an accessory gene required for full urease activity.
The sequences of UreI from
H. pylori
and the AmiS proteins, encoded by the aliphatic amidase operons of
Pseudomonas aeruginosa
and Rhodococcus sp. R312, are similar (5, 27). Aliphatic amidases catalyze the intracellular hydrolysis of short-chain aliphatic amides to produce the corresponding organic acid and ammonia. It has been shown that
H. pylori
also has such an aliphatic amidase, which hydrolyzes acetamide and propionamide in vitro (23).
In view of the sequence similarity between UreI and AmiS together with the very similar structures of the urease and amidase substrates (urea: NH
2
—CO—NH
2
and acetamide: CH
3
—CO—NH
2
) and the production of ammonia by both enzymes, a better understanding of the function of the
H. pylori
UreI protein is required. This understanding will open new opportunities for the prevention and treatment of
H. pylori
infections.
SUMMARY OF THE INVENTION
This invention provides methods for identifying molecules capable of inhibiting the growth and/or survival of Helicobacter species, particularly,
H. pylori
, in vivo. In particular, the methods of this invention involve screening molecules that specifically inhibit UreI protein function.
The invention encompasses the molecules identified by the methods of this invention and to the use of the molecules by the methods of this invention to treat or prevent Helicobacter, and particularly
H. pylori
, infection in humans and animals.
Another aspect of this invention is a method of preventing or treating Helicobacter species infection by administration to a human or animal in need of such treatment a molecule capable of inhibiting the growth and/or survival of Helicobacter species in vivo. One such molecule according to this invention is characterized by a high affinity for UreI, which allows it either to be transported inside the Helicobacter cell or to inhibit export properties of UreI. By inhibiting UreI, such molecule renders the bacteria more sensitive to acidity.
Yet another aspect of this invention is the production of immunogenic UreI antigens and their use as vaccines to prevent Helicobacter species infection and/or colonization of the gut. Antibodies to these UreI antigens are also encompassed within the scope of this invention.
This invention further relates to recombinant strains of
H. pylori
comprising a modified ureI gene, such that the products of the modified gene contribute to the attenuation of the bacteria's ability to survive in vivo, and thus, its pathogenic effects.


REFERENCES:
patent: 5472695 (1995-12-01), Neeman et al.
patent: 5560912 (1996-10-01), Neeman et al.
patent: 5695931 (1997-12-01), Labigne et al.
patent: 5843460 (1998-12-01), Labigne et al.
patent: 5876946 (1999-03-01), Burbaum et al.
patent: 5942409 (1999-08-01), Sachs et al.
patent: 0367 644 (1990-05-01), None
patent: 0 745 674 (1996-05-01), None
patent: WO 91 09049 (1991-06-01), None
patent: 93/07273 (1993-04-01), None
patent: 94/09823 (1994-05-01), None
patent: 94/26901 (1994-11-01), None
patent: WO 96 33732 (1996-10-01), None
patent: WO 96 40893 (1996-12-01), None
patent: 96/40893 (1996-12-01), None
Labigne et al, J. Bacteriol., Mar. 1991, vol. 173(6), pp. 1920-1931.
Cussac et al, J. Bacteriol. Apr. 1992, vol. 174(8), pp. 2466-2473.
Eaton et al, Infection Immunity, Jul. 1991, vol. 5967), pp. 2470-2475.
Ferrero et al, Microbial Ecology in Health and Disease, vol. 4, pp. 121-134, 1991.
Akada et al, Gut, vol. 41(suppl.1), pp. A7-A8, Sep. 11-14, 1997.
V. Cussac et al., “Expression ofHelicobacter pyloriUrease Activity inEscherichia coliHost Strains”, Society for Microbial Ecology and Disease, vol. 4(S), Oct. 1991, p. S139, Abstract H4-4.
Sugiyama, et al., “A Novel Enzyme Immunoassay for Serodiagnosis ofHelicobacter pyloriInfection”, Gastroenterology, 101:77-83 (1991).
V. Cussac et al., Expression ofHelicobacter pyloriUrease Genes inEscherichia coliGrown under Nitrogen-Limiting Conditions, Journal of Bacteriology 174(8):2466-2473 (Apr. 1992).
R. Ferrero et al., “Construction of Urease Deficient Mutants ofHelicobacter pyloriBy Allelic Exchange”, Society for Microbial Eccology and Disease, vol. 4(S), Oct. 1991, p. S139, Abstract H4-4.
A. Labigne et al., Bull. Acad. Natle. Med. 175(6):791-802 (1991).
S. Skouloubris, J-M Thiberge, A. Labigne, H. DeReuse: “TheHelicobacter PyloriUrel Protein is Not Invovled in Urease Activity But Is Essential For Bacterial Survival In Vivo” Infection And Immunity, vol. 66, No. 9, Sep. 1988, pp. 4517-4521.
M. Clynye, A. Labigne, B. Drumm:Helicobacter PyloriRequires An Acidic Environment To Survive In The Presence Of Urea: Infection And Immunity, vol. 63, No. 5, May 1995 pp. 1669-1673.
D.R. Scott, D. Weeks, C. Hong, S. Postius, K. Melchers, G. Sachs: “The Role Of Internal Urease in Acid Resistance ofHelicobacter Pylori” Gastroenterology, vol. 114, Jan. 1998, pp. 58-70.

Affiliated with

Also associated with

Rating

Methods of inhibiting Helicobacter pylori does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of inhibiting Helicobacter pylori, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting Helicobacter pylori will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2614926